ArticleFrontiers in immunology2026
TEFM drives cartilage degeneration in osteoarthritis via the ROS-AKT/NF-κB signaling axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the role and underlying mechanism of mitochondrial transcription elongation factor TEFM in osteoarthritis (OA) cartilage degeneration. Methods: Bioinformatics analysis based on the GSE114007 human knee cartilage dataset and two-sample Mendelian randomization (MR) analysis were performed to evaluate the association between TEFM and knee OA. Human cartilage specimens were collected to verify TEFM expression patterns. Lentivirus-mediated TEFM knockdown was performed in ATDC5 chondrocytes, and an Results: TEFM expression was significantly upregulated in OA cartilage, and MR analysis supported a potential causal association with knee OA risk. Conclusion: TEFM facilitates OA cartilage degeneration via the ROS-AKT/NF-κB axis, which provides a novel therapeutic target for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.